Expert Interview
Reviewing the Potential of Vyvgart from Argenx Ahead of its May 10th FDA PDUFA Date for Broader Use Across Myasthenia Gravis and CIDP Subtypes
Ticker(s): ARGX, UCBJY, JNJ, AMGN, AZNInstitution: Icahn School of Medicine at Mount Sinai
Professor of Neurology, Director of Clinical Neurophysiology Laboratories, and Director of Neuromuscular Disorders Division at Icahn School of Medicine at Mount Sinai
Manages 50 patients with myasthenia gravis and 50 with chronic inflammatory demyelinating polyneuropathy
- Specializes in neuromuscular diseases, clinical neurophysiology, and Neuro-AIDS; directs key clinical labs and is a recognized expert in botulinum toxin therapy
How many patients do you manage with Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for the potential VYVGART expanded use in Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
Added By: lilly_adminWhat percentage of your MG patients are AChR-Ab seronegative?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
